HRP20220932T1 - Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid - Google Patents

Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid Download PDF

Info

Publication number
HRP20220932T1
HRP20220932T1 HRP20220932TT HRP20220932T HRP20220932T1 HR P20220932 T1 HRP20220932 T1 HR P20220932T1 HR P20220932T T HRP20220932T T HR P20220932TT HR P20220932 T HRP20220932 T HR P20220932T HR P20220932 T1 HRP20220932 T1 HR P20220932T1
Authority
HR
Croatia
Prior art keywords
composition
cyclodextrin
use according
liver
diol
Prior art date
Application number
HRP20220932TT
Other languages
English (en)
Croatian (hr)
Inventor
Shunlin Ren
Leyuan XU
Yanxia NING
Jin Koung Kim
Weiqi Lin
Meej KIM
Andrew R. Miksztal
Hongwei WU
Min L. Lee
Wilma Tamraz
Original Assignee
Virginia Commonwealth University
The United States Government As Represented By The Department Of Veterans Affairs
Durect Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University, The United States Government As Represented By The Department Of Veterans Affairs, Durect Corporation filed Critical Virginia Commonwealth University
Publication of HRP20220932T1 publication Critical patent/HRP20220932T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HRP20220932TT 2016-08-02 2017-08-01 Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid HRP20220932T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662370024P 2016-08-02 2016-08-02
US201762470578P 2017-03-13 2017-03-13
EP17837516.8A EP3494125B1 (en) 2016-08-02 2017-08-01 Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
PCT/US2017/044840 WO2018026781A1 (en) 2016-08-02 2017-08-01 Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Publications (1)

Publication Number Publication Date
HRP20220932T1 true HRP20220932T1 (hr) 2022-10-28

Family

ID=61073854

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220932TT HRP20220932T1 (hr) 2016-08-02 2017-08-01 Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid

Country Status (23)

Country Link
US (4) US20190269695A1 (enExample)
EP (2) EP4101861A1 (enExample)
JP (3) JP2019524772A (enExample)
KR (3) KR20230152787A (enExample)
CN (2) CN109983025B (enExample)
AU (2) AU2017305239C1 (enExample)
CA (1) CA3031224A1 (enExample)
CY (1) CY1125567T1 (enExample)
DK (1) DK3494125T3 (enExample)
EA (1) EA201990438A1 (enExample)
ES (1) ES2922933T3 (enExample)
HR (1) HRP20220932T1 (enExample)
HU (1) HUE059768T2 (enExample)
IL (2) IL298681A (enExample)
LT (1) LT3494125T (enExample)
MX (2) MX2019001323A (enExample)
PL (1) PL3494125T3 (enExample)
PT (1) PT3494125T (enExample)
RS (1) RS63529B1 (enExample)
SI (1) SI3494125T1 (enExample)
SM (1) SMT202200330T1 (enExample)
TW (1) TWI815796B (enExample)
WO (1) WO2018026781A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
AU2014369916A1 (en) 2013-12-24 2016-06-16 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
PT3494125T (pt) 2016-08-02 2022-07-07 Durect Corp Composições compreendendo 5-colesten-3, 25-diol, 3-sulfato (25hc3s), ou seu sal farmaceuticamente aceitável, e, pelo menos, um oligossacárido cíclico
EP4037650A4 (en) * 2019-09-30 2023-10-18 Durect Corporation Treatment of alcoholic hepatitis
IL294286A (en) * 2019-12-27 2022-08-01 Durect Corp Crystalline and liquid crystalline sodium 25-hydroxycholine-5-yne-5-sulfate and methods for its preparation
AU2021221109A1 (en) * 2020-02-11 2022-08-25 Durect Corporation Treatment of infectious diseases
WO2021202608A1 (en) * 2020-03-31 2021-10-07 The Regents Of The University Of Michigan Serum metabolites as biomarkers for carnitine treatment of sepsis
AU2021273936A1 (en) * 2020-05-22 2022-12-08 Durect Corporation Treatment of non-alcoholic steatohepatitis (NASH)
JP2023531735A (ja) * 2020-06-26 2023-07-25 デュレクト コーポレーション インスリン抵抗性、糖尿病、及び前糖尿病の少なくとも１つを処置するための酸素化コレステロールスルフェート類の使用
CN112967234B (zh) * 2021-02-09 2022-12-09 复旦大学附属中山医院 冠状动脉功能生理学病变模式定量评价方法
WO2022272103A1 (en) * 2021-06-25 2022-12-29 Durect Corporation 25-hydroxy-cholest-5-en-3-sulfate choline and methods for preparing, and uses of, same
CN113750039B (zh) * 2021-10-26 2023-08-18 浙江中医药大学 一种黄芩苷-海藻酸钙温敏纳米凝胶、制备方法及其应用
WO2023196412A1 (en) * 2022-04-06 2023-10-12 Nobias Therapeutics, Inc. Liquid formulations comprising mitogen-activated protein kinase kinase (mek) inhibitors and methods using same
CN119896674A (zh) * 2023-10-27 2025-04-29 上海交通大学医学院附属新华医院 胆固醇硫酸酯在制备治疗特应性皮炎的药物中的应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
BE794362A (fr) 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3928397A (en) 1973-03-02 1975-12-23 Eisai Co Ltd New 5-cholestene derivatives and preparation thereof
US3822254A (en) 1973-05-21 1974-07-02 Hoffmann La Roche Synthesis of 25-hydroxycholesterol
US4264512A (en) 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4202891A (en) 1977-05-16 1980-05-13 Kandutsch Andrew A 15-Oxygenated sterol compounds and the use of such compounds to inhibit the biosynthesis of sterols
GB1595020A (en) 1977-06-24 1981-08-05 Chugai Pharmaceutical Co Ltd 3a-hydroxy steroid derivatives of the cholestane series
US4427668A (en) 1982-04-01 1984-01-24 New York University 26-Hydroxycholesterol and derivatives and analogs thereof in regulation of cholesterol accumulation in body tissue
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5510340A (en) 1992-06-12 1996-04-23 Sri International Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
US5371077A (en) 1992-08-03 1994-12-06 William Marsh Rice University Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them
US5599659A (en) 1993-03-11 1997-02-04 Breonics, Inc. Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate
US5587368A (en) * 1993-11-30 1996-12-24 New York University Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury
PL185622B1 (pl) 1995-06-23 2003-06-30 Novo Nordisk As Zastosowanie związku steroidowego i sposób regulacji mejozy w komórce rozrodczej ssaka
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US7012069B2 (en) 2001-05-03 2006-03-14 Arch Development Corporation Liver X receptor agonists
DE69913513T2 (de) 1998-05-13 2004-09-30 Novo Nordisk A/S Verwendung von verbindungen mit der fähigkeit die meiose zu regulieren
IL139241A0 (en) 1998-05-13 2001-11-25 Novo Nordisk As Meiosis regulating compounds
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
BR0010197A (pt) 1999-04-30 2002-07-16 Arch Dev Corp Derivados de esteróides
US20060025393A1 (en) 1999-04-30 2006-02-02 Shutsung Liao Steroid derivatives
WO2001015676A2 (en) 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
JP4018312B2 (ja) 2000-02-21 2007-12-05 株式会社ルネサステクノロジ 無線通信装置
IN191090B (enExample) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
EP1385868A4 (en) 2001-02-08 2004-12-08 Univ Chicago STEROID DERIVATIVE
US20020164310A1 (en) 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
DE60327225D1 (de) * 2002-08-20 2009-05-28 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
WO2006003150A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
CA2637884A1 (en) 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
DE102006021181B3 (de) 2006-05-06 2007-05-03 Laux, Thomas, Dr. Zahnprothesen-Trägerimplantat
GB0625965D0 (en) 2006-12-23 2007-02-07 Renovo Ltd Medicaments for wound healing
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
US8831674B2 (en) 2007-09-27 2014-09-09 Multi-Tech Systems, Inc. Message server
RU2460525C2 (ru) 2008-01-04 2012-09-10 Эл Джи Лайф Сайенсиз Лтд. Производные индола и индазола, обладающие консервирующим действием по отношению к клеткам, тканям и органам
WO2011077245A2 (en) 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
WO2012017290A1 (en) * 2010-08-04 2012-02-09 Carlo Ghisalberti Inclusion complexes of cyclodextrins with spermidine, and proliferative/reparative compositions comprising thereof
KR101739816B1 (ko) * 2010-12-01 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
FI2753632T3 (fi) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
JP6125610B2 (ja) * 2012-04-12 2017-05-10 ヴァージニア コモンウェルス ユニバーシティ 代謝障害、高脂血症、糖尿病、脂肪性肝疾患及びアテローム性動脈硬化症の治療のための新規コレステロール代謝物、５−コレステン−３β，２５−ジオールジスルファート（２５ＨＣＤＳ）
WO2014015024A2 (en) 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
WO2014121235A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
EP2842547A1 (en) * 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
AU2014369916A1 (en) 2013-12-24 2016-06-16 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
EP3204011A4 (en) * 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
MX376196B (es) 2014-10-10 2025-03-07 Univ Virginia Commonwealth Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno del almacenamiento lipidico.
EP3328389A1 (en) 2015-07-27 2018-06-06 Catacore, Inc. Compositions for the treatment of cataracts
PT3494125T (pt) 2016-08-02 2022-07-07 Durect Corp Composições compreendendo 5-colesten-3, 25-diol, 3-sulfato (25hc3s), ou seu sal farmaceuticamente aceitável, e, pelo menos, um oligossacárido cíclico
BR112019001193A2 (pt) 2016-08-02 2019-04-30 Virginia Commonwealth University uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamatória e lesões de pele
BR112019001225A2 (pt) 2016-08-02 2019-04-30 Durect Corporation composições compreendendo sulfato de colesterol oxigenado e pelo menos um dentre polialquileno glicol, carboximetil celulose e polioxilglicerídeo
EP4037650A4 (en) 2019-09-30 2023-10-18 Durect Corporation Treatment of alcoholic hepatitis
IL294286A (en) 2019-12-27 2022-08-01 Durect Corp Crystalline and liquid crystalline sodium 25-hydroxycholine-5-yne-5-sulfate and methods for its preparation
AU2021221109A1 (en) 2020-02-11 2022-08-25 Durect Corporation Treatment of infectious diseases
AU2021273936A1 (en) 2020-05-22 2022-12-08 Durect Corporation Treatment of non-alcoholic steatohepatitis (NASH)
US20230181602A1 (en) 2020-05-22 2023-06-15 Durect Corporation Treatment of non-alcoholic steatohepatitis (nash)
JP2023531735A (ja) 2020-06-26 2023-07-25 デュレクト コーポレーション インスリン抵抗性、糖尿病、及び前糖尿病の少なくとも１つを処置するための酸素化コレステロールスルフェート類の使用

Also Published As

Publication number Publication date
CN109983025B (zh) 2023-04-04
MX2019001323A (es) 2019-07-04
EP3494125A4 (en) 2020-04-01
CN109983025A (zh) 2019-07-05
JP2019524772A (ja) 2019-09-05
AU2017305239A1 (en) 2019-02-21
TW201818945A (zh) 2018-06-01
EP3494125B1 (en) 2022-06-22
CY1125567T1 (el) 2026-02-25
EA201990438A1 (ru) 2019-08-30
IL298681A (en) 2023-01-01
US20250249021A1 (en) 2025-08-07
EP3494125A1 (en) 2019-06-12
SMT202200330T1 (it) 2022-11-18
KR102593667B1 (ko) 2023-10-24
AU2017305239C1 (en) 2022-08-18
CN116747233A (zh) 2023-09-15
IL264390A (en) 2019-02-28
KR20230152787A (ko) 2023-11-03
AU2017305239B2 (en) 2022-03-17
AU2022204217A1 (en) 2022-07-07
WO2018026781A1 (en) 2018-02-08
ES2922933T3 (es) 2022-09-21
US20210169898A1 (en) 2021-06-10
DK3494125T3 (da) 2022-08-01
RS63529B1 (sr) 2022-09-30
US20230047788A1 (en) 2023-02-16
KR20190035776A (ko) 2019-04-03
MX2022013429A (es) 2022-11-14
IL264390B2 (en) 2023-04-01
KR102465046B1 (ko) 2022-11-10
US20190269695A1 (en) 2019-09-05
AU2022204217B2 (en) 2024-04-04
IL264390B (en) 2022-12-01
TW202426000A (zh) 2024-07-01
US12226423B2 (en) 2025-02-18
EP4101861A1 (en) 2022-12-14
JP2022169550A (ja) 2022-11-09
TWI815796B (zh) 2023-09-21
US11406646B2 (en) 2022-08-09
JP2024105442A (ja) 2024-08-06
PT3494125T (pt) 2022-07-07
LT3494125T (lt) 2022-11-10
SI3494125T1 (sl) 2022-10-28
PL3494125T3 (pl) 2022-10-17
CA3031224A1 (en) 2018-02-08
JP7487264B2 (ja) 2024-05-20
HUE059768T2 (hu) 2022-12-28
KR20220154250A (ko) 2022-11-21

Similar Documents

Publication Publication Date Title
JP2019524772A5 (enExample)
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
US8586770B2 (en) Unsaturated steroid compounds
US12318364B2 (en) Isoflavonoid compositions and methods for the treatment of cancer
JP2017519018A5 (enExample)
HRP20191216T1 (hr) Formulacije testosterona
JP7358337B2 (ja) レシニフェラトキシンの製剤
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
JP2011504870A (ja) ビタミンｄ誘導体および任意にステロイド系抗炎症剤を含む、ワセリンフリーの軟膏形態にある新規組成物
JP2019504056A5 (enExample)
HRP20210523T1 (hr) Pripravci i postupci za liofilne oblike nanočestica
Carvalho et al. Inclusion complex between β-cyclodextrin and hecogenin acetate produces superior analgesic effect in animal models for orofacial pain
UA121232C2 (uk) Композиції для місцевого застосування, що містять кортикостероїд
EA201990438A1 (ru) Композиции, содержащие 5-холестен-3,25-диол, 3-сульфат (25hc3s) или его фармацевтически приемлемую соль и по меньшей мере один циклический олигосахарид, и способы их применения
JP2016513650A (ja) 白檀油を含む安定化クリーム製剤
Gao et al. Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect
Putheti et al. Nasal Drug delivery in Pharmaceutical and biotechnology: present and future.
Didamoony et al. Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
HRP20201300T1 (hr) Liofilizirani pripravak citotoksičnih dipeptida
CN105777854A (zh) 硫酸依替米星的药物组合物及其在生物医药中的应用
CN104873469A (zh) 一种注射用七叶皂苷钠冻干乳剂的制备方法
BRPI0821739B8 (pt) sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica e método de preparação de sistema de liberação de droga
Gowda et al. Sex-specific effect of ethanol on colonic short-chain fatty acids and derivatives in the mouse model using targeted LC/MS
MX2017008264A (es) Formulaciones inyectables de paracetamol.
Rodrigues et al. Pharmacodynamic and Pharmacokinetic Studies of β-Cyclodextrin: Dexamethasone Acetate Complexes in Mice